Recent Updates
Recently added Catalysts
AGEN Positive Sentiment

Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer

Wednesday, August 26, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Agenus Inc. has published updated results from the Phase 2 NEST trial, which evaluates neoadjuvant botensilimab and balstilimab in patients with resectable colon cancer. The findings indicate significant deep pathologic responses and no recurrences observed among participants. This publication highlights the potential of these therapies in treating localized mismatch repair-deficient colon cancer.

Market Sentiment Analysis

POSITIVE FACTORS

  • Updated results show deep pathologic responses.
  • No observed recurrences reported in patients.
  • The trial demonstrates promising outcomes for resectable colon cancer.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+52%
120-day peak, hindsight
Typical move
6.2%
average across 4 past catalysts
Cash runway
~1 mo
High dilution risk
Lead asset
Botensilimab
Phase 1 · Pancreatic Cancer Metastatic

Full Press Release Details

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of updated results from the investigator-sponsored Phase 2 NEST trial evaluating neoadjuvant botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, and balstilimab (BAL), Agenus’ anti-PD-1 antibody, in patients with resectable colon cancer. The manuscript, titled “Neoadjuvant botensilimab/balstilimab for localized mismatch r

Frequently Asked Questions

What is the NEST trial?

The NEST trial is a Phase 2 study evaluating neoadjuvant botensilimab and balstilimab in resectable colon cancer.

What were the results of the NEST trial?

The trial reported deep pathologic responses and no observed recurrences in patients.

What are botensilimab and balstilimab?

Botensilimab is an anti-CTLA-4 antibody, and balstilimab is an anti-PD-1 antibody developed by Agenus.

Who sponsored the NEST trial?

The NEST trial was investigator-sponsored.

What type of cancer was studied in the NEST trial?

The trial focused on patients with resectable colon cancer.

ShareAdd on Google
Tags: AGEN Viatris Investor Conferences Healthcare Agenus NEST trial botensilimab balstilimab colon cancer
Last updated: Aug 26, 2026

Biotech snapshot

Cash runway
$19M liquidity · $10M/mo burn
~1 mo
High dilution risk
Lead asset
BotensilimabPhase 1
Pancreatic Cancer Metastatic →

Catalyst track record

+52%
best trade around AGEN's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for AGEN.

See every catalyst's timing & PoA →